(CercleFinance.com) – Grifols shares rose nearly 6% on the Madrid Stock Exchange on Monday following the publication of the 2021 annual results of the Spanish specialist in drugs derived from human plasma.
The Barcelona-based group reported this morning a current operating profit (Ebitda) of 961.5 million euros for the past year, down from the 1,324 million euros generated over the financial year. 2020.
Annual revenue is also down, at 4.93 billion euros, which represents a decline of 3.7% at constant exchange rates and 7.6% in published data.
In its press release, Grifols justifies the decline in its revenues and its annual results by a decrease in plasma collection which it explains by the Covid-19 epidemic.
The Spanish health care group – which transforms human plasma into drugs to treat rare and chronic diseases – nevertheless says it anticipates a return to growth and an improvement in its profitability this year, against a background of normalization of the volumes of collected plasma.
Its turnover and profit margins should thus gradually improve throughout the 2022 financial year, he promises.
Following these statements, Grifols shares climbed 5.7% late Monday afternoon on the IBEX 35 index.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
